Jazz Pharmaceuticals
JAZZ
306 hedge funds and large institutions have $7.59B invested in Jazz Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 88 increasing their positions, 122 reducing their positions, and 36 closing their positions.
91% more call options, than puts
Call options by funds: $112M | Put options by funds: $58.5M
53% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 36
34% more capital invested
Capital invested by funds: $5.68B → $7.59B (+$1.91B)
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
3% more funds holding
Funds holding: 296 → 306 (+10)
0.52% more ownership
Funds ownership: 87.01% → 87.52% (+0.52%)
28% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 122
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$406M |
| 2 |
SIG
Senator Investment Group
New York
|
+$97.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$65.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$64.7M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$61.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
-$82.6M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$54.2M |
| 3 |
Renaissance Technologies
New York
|
-$52M |
| 4 |
CCM
Cadian Capital Management
New York
|
-$41.9M |
| 5 |
Two Sigma Investments
New York
|
-$35.3M |
JAZZ Hedge Fund Activity: Q1 2017 in Review
306 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2017, worth a combined $7.59B — up 34% from $5.68B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new JAZZ positions and 36 closed out — a net gain of 19 holders — while 88 added to existing stakes and 122 trimmed.
The largest buyer was BlackRock, adding an estimated $406M. The largest seller was Tourbillon Capital Partners, cutting an estimated $82.6M.
- 306 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2017, up from 296 in Q4 2016.
- Funds reported $7.59B of Jazz Pharmaceuticals stock for Q1 2017, up 34% quarter-over-quarter.
- 55 funds opened new Jazz Pharmaceuticals positions in Q1 2017 and 36 closed out, a net change of +19 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $406M added.
- The largest Jazz Pharmaceuticals seller in Q1 2017 was Tourbillon Capital Partners, an estimated $82.6M sold.
Based on aggregated 13F filings for Q1 2017.